- This event has passed.
Dr. Samantha Bevill of Dana-Farber Cancer Institute & Broad Institute of MIT and Harvard Presents
Samantha Bevill, PhD, is a pharmacologist specializing in the mechanisms of therapeutic resistance in aggressive cancers. She earned her B.S. in Microbiology from Clemson University and her Ph.D. in Pharmacology from the University of North Carolina at Chapel Hill. Under the mentorship of Dr. Gary Johnson, her doctoral research utilized advanced proteomics and genomics to map compensatory kinase signaling pathways in breast cancer. Currently, as a postdoctoral fellow in Dr. Bradley Bernstein’s laboratory, Dr. Bevill investigates the transcriptional regulatory landscapes of aggressive sarcomas. Her work has uncovered a novel role for MDM2 in driving therapeutic resistance. Dr. Bevill’s most recent work, which is co-advised by Dr. Jun Qi, bridges basic mechanistic discovery and therapeutic application, developing chemical biology strategies to leverage MDM2’s E3 ligase activity for tumor-specific protein degradation.
Date/Time: June 9, 2026 at 4:00 PM
Location: Genetic Medicine Building 4007
Host: UNC Lineberger & Pharmacology
Event Flyer: index.php